What is PLUR's current stock price?

PLUR (Pluri Inc.) is currently trading at $2.37 with a market cap of $21.3M.

What sector is Pluri Inc. in?

Pluri Inc. (PLUR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PLUR a good stock to buy?

Analysts have a Buy consensus on PLUR with a price target of $12.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PLUR Pluri Inc.

Healthcare

$2.37+3.22%ClosedMarket Cap: $21.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-1.28

P/S

19.78

EV/EBITDA

-1.93

DCF Value

$-19.26

FCF Yield

-101.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

19.0%

Operating Margin

-2412.1%

Net Margin

-2424.7%

ROE

203.6%

ROA

-100.4%

ROIC

-117.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$167.0K	$-6.2M	$—
Q2 null	$198.0K	$-6.5M	$—
Q1 null	$316.0K	$-5.8M	$—
Q4 null	$398.0K	$-7.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Manieu Alexandre Weinsteindirector, 10 percent owner:

SellMon May 04

Manieu Alexandre Weinsteindirector, 10 percent owner:

SellMon Jan 05

Zalts Liatofficer: Chief Financial Officer

SellMon Dec 08

YANAY YAKYdirector, officer: Chief Executive Officer

SellMon Dec 08

Shemesh-Rasmussen Maitaldirector

SellMon Dec 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.75

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Peers